# Progress Note 07 — Focused Visit (Care-plan review)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Booker T. Washington (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI017-SYN-TD
- Date: 1915-10-26
- Fictional facility: St. Posthumous Health Center
- Fictional author: Lorraine Whitfield, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Care-plan review)

## Chief complaint

Six-month blood pressure and chronic kidney disease review. **S**

## History of present illness

Mr. Washington returns for his six-month review. The back strain in August cleared in about ten days, and he has taken no NSAIDs since. His home readings run in the high 110s to low 120s systolic, with no dizziness on standing. His headaches have not returned, and his concentration is better than in the spring, though he still tires by evening on travel days. He walks 20 to 30 minutes on most days at home. He gets up once a night to urinate and has had no genital symptoms on dapagliflozin. He received the influenza and first zoster vaccines last month. He asked last month to learn more about what would happen if his kidney function fell further. **S**

| Element | Detail |
|---|---|
| Interval history | August back strain resolved; no NSAIDs since |
| Home blood pressure | High 110s to low 120s systolic; no dizziness |
| Symptoms | No headaches; concentration better; tires on travel days |
| Activity | Walking 20 to 30 minutes on most days |
| Patient question | What happens if his kidney function falls further |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Tires by evening on travel days; weight stable |
| Eyes | Negative | No new blurring or loss of vision |
| Cardiovascular | Negative | No chest pain, palpitations, or ankle swelling |
| Genitourinary | Negative | Up once a night; no dysuria or genital symptoms |
| Musculoskeletal | Negative | Back pain resolved |
| Neurological | Negative | No headache or dizziness on standing |
| Psychiatric | Negative | Mood steady; PHQ-9 score 2 |

7 systems reviewed. **S**

## Current medications

- Amlodipine 10 mg oral tablet, one tablet by mouth daily **S**
- Losartan 100 mg oral tablet, one tablet by mouth daily **S**
- Dapagliflozin 10 mg oral tablet, one tablet by mouth daily **S**
- Chlorthalidone 25 mg oral tablet, one-half tablet (12.5 mg) by mouth daily **S**
- Atorvastatin 20 mg oral tablet, one tablet by mouth daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 118/76 mmHg; pulse 72 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 70.5 kg; BMI 24.4 kg/m². All vital signs are synthetic.

Sodium: 136 mmol/L; Potassium: 4.5 mmol/L; Bicarbonate (total CO2): 23 mmol/L; BUN: 34 mg/dL (high); Creatinine: 2.3 mg/dL (high); eGFR: 32 mL/min/1.73 m² (low); Glucose: 93 mg/dL; Calcium: 9.2 mg/dL; Phosphate: 4 mg/dL; Intact PTH: 78 pg/mL (high); Hemoglobin: 12.8 g/dL (low); Urine albumin-creatinine ratio: 240 mg/g (high); KFRE 2-year kidney failure risk: 6.5%; KFRE 5-year kidney failure risk: 18.8%; PHQ-9: 2. All results are synthetic.

## Change since baseline

- Sodium: 139 mmol/L at baseline, 136 mmol/L at this visit **S**
- Potassium: 4.4 mmol/L at baseline, 4.5 mmol/L at this visit **S**
- Bicarbonate (total CO2): 21 mmol/L (low) at baseline, 23 mmol/L at this visit **S**
- BUN: 34 mg/dL (high) at baseline, 34 mg/dL (high) at this visit **S**
- Creatinine: 2.1 mg/dL (high) at baseline, 2.3 mg/dL (high) at this visit **S**
- eGFR: 36 mL/min/1.73 m² (low) at baseline, 32 mL/min/1.73 m² (low) at this visit **S**
- Glucose: 92 mg/dL at baseline, 93 mg/dL at this visit **S**
- Calcium: 9.1 mg/dL at baseline, 9.2 mg/dL at this visit **S**
- Phosphate: 4.2 mg/dL at baseline, 4 mg/dL at this visit **S**
- Intact PTH: 92 pg/mL (high) at baseline, 78 pg/mL (high) at this visit **S**
- Hemoglobin: 12.6 g/dL (low) at baseline, 12.8 g/dL (low) at this visit **S**
- Urine albumin-creatinine ratio: 820 mg/g (high) at baseline, 240 mg/g (high) at this visit **S**
- PHQ-9: 4 at baseline, 2 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well |
| Blood pressure | 118/76 mmHg, the average of two seated readings after five minutes' rest; no fall on standing |
| Heart | Regular rhythm, rate 72; soft S4 |
| Lungs | Clear |
| Extremities | No edema |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Severe hypertension with hypertensive kidney disease, at target** (I12.9). Standardized office blood pressure 118/76 mmHg, meeting the KDIGO systolic target below 120 without dizziness. **S**
   - No change.
2. **Chronic kidney disease stage G3b A3** (N18.32). eGFR 32, stable after the early dip (36 at diagnosis, 30 on full therapy); urine albumin-creatinine ratio 240 mg/g, down 71 percent from 820; potassium 4.5 and bicarbonate 23. Kidney failure risk 6.5 percent at 2 years and 18.8 percent at 5 years: high. The 5-year risk is above the threshold for nephrology care, and the 2-year risk is below 10 percent. **S**
   - Continue losartan 100 mg and dapagliflozin 10 mg.
   - Send today's results and risk scores to nephrology for his next review, with his request to discuss dialysis and conservative care.
   - eGFR, urine albumin, and a basic metabolic panel about every four months.
3. **Mild anemia of chronic kidney disease** (D63.1). Hemoglobin 12.8 g/dL, stable since May. **S**
   - Hemoglobin yearly; iron studies if it falls.
4. **Mineral and bone disorder of chronic kidney disease, surveillance**. Calcium 9.2 and phosphate 4.0 mg/dL, normal; PTH 78 pg/mL, down from 92. The baseline vitamin D level has still not been drawn. **S**
   - 25-hydroxyvitamin D with the next draw.
   - Calcium, phosphate, and PTH every 6 to 12 months.
5. **Hypertensive retinopathy, both eyes** (H35.033). No visual symptoms. **S**
   - Dilated eye examination in May.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Basic metabolic panel | With each eGFR draw | Completed today | Potassium 4.5, bicarbonate 23, creatinine 2.3 mg/dL, eGFR 32 |
| Laboratory | eGFR and urine albumin-creatinine ratio | About 3 times a year for G3b A3 | Completed today | eGFR 32; urine albumin-creatinine ratio 240 mg/g, down 71 percent from 820. The third pair since diagnosis, on schedule |
| Laboratory | Calcium, phosphate, and PTH | Every 6 to 12 months in G3b | Completed today | Calcium 9.2, phosphate 4.0, PTH 78 pg/mL (down from 92) |
| Laboratory | 25-hydroxyvitamin D | Once at baseline | Deferred | Not drawn at diagnosis or with today's calcium, phosphate, and PTH, a deviation from the protocol. PTH is falling with normal calcium and phosphate, so no harm is evident. Corrective action: added to the next draw |
| Laboratory | Hemoglobin | At least yearly in G3 | Completed today | 12.8 g/dL, stable |
| Laboratory | Iron studies | At anemia diagnosis; repeat with a fall in hemoglobin or on an ESA | Not indicated | Iron replete in May; hemoglobin stable and no ESA |
| Survey | Kidney failure risk equation, 2 and 5 years | Yearly in G3 to G5 | Completed today | 6.5 percent at 2 years and 18.8 percent at 5 years; the 5-year risk is above the 3 to 5 percent referral threshold, confirming nephrology care |
| Referral | Nephrology | 5-year kidney failure risk of 3 to 5 percent or more, or persistent A3 albuminuria | Up to date | Seen in May; today's results, risk scores, and his question about kidney failure options sent ahead of his next nephrology review |
| Laboratory | Urinalysis with microscopy | With a change in status | Not indicated | No change in status: albuminuria fell by 71 percent and eGFR is stable. The missing baseline urinalysis is recorded as a deviation at the one-week visit |
| Laboratory | Cystatin C | When a decision hinges on a more accurate eGFR | Not indicated | No dosing or referral decision depends on it now |
| Laboratory | Alkaline phosphatase | Yearly in G4 to G5 | Not indicated | eGFR 32 is stage G3b |
| Laboratory | Lipid panel | Once at diagnosis in chronic kidney disease; yearly when stable in the lipid monograph | Not indicated | No repeat LDL, per the CKD monograph and KDIGO; a deliberate departure from the lipid monograph |
| Laboratory | HbA1c | Yearly in hypertension | Up to date | 5.4 percent in May; glucose 93 mg/dL today |
| Examination | Standardized office blood pressure | Every visit; target systolic below 120 when tolerated | Completed today | 118/76 mmHg; systolic target met |
| Examination | Weight, BMI, and cardiac auscultation | Every visit | Completed today | 70.5 kg, BMI 24.4; soft S4 |
| Examination | Funduscopic examination | Yearly in chronic hypertension | Up to date | Dilated examination in May; unchanged on undilated examination last month; next in May |
| Imaging | ECG and echocardiogram | At diagnosis; repeat as clinically indicated | Not indicated | Left ventricular hypertrophy documented in May; no new symptoms |
| Examination | Peripheral pulses and ankle-brachial index | Every 2 to 3 years at 65 or older or with a smoking history | Not indicated | Age 59 and a never smoker |
| Survey | 10-year ASCVD risk estimate | Yearly in hypertension | Not indicated | Already on a statin for the chronic kidney disease indication, so the estimate would not change treatment |
| Survey | PHQ-9 | Yearly in hypertension | Completed today | Score 2 |
| Medication safety | Medication review: NSAID avoidance and kidney dosing | Every visit | Completed today | No NSAIDs since the August naproxen; the pharmacy flag is in place |
| Medication safety | Vaccination review | Yearly in chronic kidney disease | Due | Influenza and zoster dose 1 given last month; zoster dose 2 due from next month; COVID-19 and RSV vaccines were discussed last month |
| Self-management | Home blood pressure log, sodium below 2 g a day, and activity | Every visit | Completed today | Walking about 120 minutes a week; goal 150. Sodium plan for travel reinforced |

## Goal progress

- Lower blood pressure below 130/80 within two months. Outcome by 1915-06-29: Blood pressure 128/80 on four medicines. **S**
- Reach a standardized office systolic pressure below 120 when tolerated by the six-month review. Outcome by 1915-10-26: Blood pressure 118/76 without dizziness. **S**
- Reduce the urine albumin-creatinine ratio by at least 30 percent by the six-month review. Outcome by 1915-10-26: UACR fell from 820 to 240 mg/g. **S**
- Keep eGFR decline after starting therapy within 30 percent and stable thereafter. Outcome by 1915-10-26: eGFR 36 at baseline, 30 on full therapy, 32 at six months. **S**

## Guideline basis

- 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025), American Heart Association and American College of Cardiology
- KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024), Kidney Disease: Improving Global Outcomes (KDIGO)
- KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease (2021), Kidney Disease: Improving Global Outcomes (KDIGO)
- CMID: Clinical Monitoring Intelligence Database, hypertension and chronic kidney disease monographs (2026), Aether Forge

## Follow-up

- PSA and hepatitis C and HIV screening from the preventive plan added to today's draw; results reviewed when they return. Zoster vaccine dose 2 from next month. Blood pressure and kidney review in about four months with eGFR, urine albumin, a basic metabolic panel, and vitamin D. Nephrology review. **S**

